Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

This article is part of the supplement: Lupus 2012: New targets, new approaches

Meeting abstract

Area-level socioeconomic status and variation in medication use among Medicaid enrollees with incident systemic lupus erythematosus, 2000 to 2004

CH Feldman1*, LT Hiraki1, J Lui1, GS Alarcón2, MA Fischer1, J Yazdany3 and KH Costenbader1

  • * Corresponding author: CH Feldman

Author affiliations

1 Brigham and Women's Hospital, Boston, MA, USA

2 University of Alabama, Birmingham, AL, USA

3 University of California, San Francisco, CA, USA

For all author emails, please log on.

Citation and License

Arthritis Research & Therapy 2012, 14(Suppl 3):A7  doi:10.1186/ar3941


The electronic version of this article is the complete one and can be found online at: http://arthritis-research.com/content/14/S3/A7


Published:27 September 2012

© 2012 Feldman et al.; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background

Differences in access to medications may be related to socioeconomic disparities in outcomes among individuals with systemic lupus erythematosus (SLE). We investigated county-level socioeconomic status (SES) and corticosteroid, hydroxychloroquine and immunosuppressant use among individuals in the low-income US Medicaid population.

Methods

From the US Medicaid Analytic eXtract (MAX) data, containing all billing claims from 2000 to 2004, we identified adults, aged 18 to 65, with incident SLE (≥3 SLE ICD-9 codes (710.0), >30 days apart, with 24 months of prior enrollment without SLE claims). Sex, age, race/ethnicity, ZIP code, and geographic region were obtained. We determined health professional shortage areas, number of state-level rheumatologists, and county-level SES using a validated composite of US Census variables. Our outcome measures were use at any time of corticosteroids, hydroxychloroquine, or an immunosuppressant (azathioprine, mycophenolate mofetil, cyclophosphamide, cyclosporine or tacrolimus). We used multivariable logistic regression to examine relationships between sociodemographic variables and medication prescriptions.

Results

Of 3,965 Medicaid enrollees with incident SLE, the mean age was 39.5 ± 12; 94.1% were female, 41.2% African American, 33.7% White, and 15.2% Hispanic. A total of 67.4% received corticosteroids, 49.5% received hydroxychloroquine, and 17.5% received an immunosuppressant. Adjusting for months of enrollment, 77.5% of patients in the lowest SES quartile received corticosteroids compared with 65.9% in the highest (OR = 1.8, 95% CI = 1.27 to 2.58). In our fully adjusted model (Table 1), increasing county-level SES among Medicaid enrollees with incident SLE was associated with a lower odds of receiving a corticosteroid prescription, but a higher odds of receiving an immunosuppressant prescription. Hydroxychloroquine use did not vary significantly by SES.

Table 1. Medication prescriptions among Medicaid enrollees with incident SLE, 2000 to 2004 according to county-level SESa

Conclusion

In higher SES areas, corticosteroid use among patients with incident SLE appears to be less frequent, while immunosuppressant use may be more frequent. Further studies are necessary to determine whether medication differences contribute to disparities in outcomes.